{"groups":[{"description":"0.15x10\\^6 Chimeric Antigen Receptor (CAR) T cells per kg of recipient bodyweight\n\nNo participants were enrolled on dose level -1.","id":"FG000","title":"Dose Escalation Cohort 1 Dose Level -1 - 0.15x10^6 Chimeric Antigen Receptor (CAR) T Cells Per kg"},{"description":"Participants who have not had an allogeneic hematopoietic stem cell transplant. 0.3x10\\^6 Chimeric Antigen Receptor (CAR) T cells per kg of recipient bodyweight\n\nStarting dose: 0.3x10\\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) infuse on day 0 and Cyclophosphamide: 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg/m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3","id":"FG001","title":"Dose Escalation Cohort 1 Dose Level 1 - 0.3x10^6 Chimeric Antigen Receptor (CAR) T Cells Per kg"},{"description":"Participants who have not had an allogeneic hematopoietic stem cell transplant. 1.0x10\\^6 Chimeric Antigen Receptor (CAR) T cells per kg of recipient bodyweight\n\n1.0x10\\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) infuse on day 0 and Cyclophosphamide: 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg/m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3","id":"FG002","title":"Dose Escalation Cohort 1 Dose Level 2 - 1.0x10^6 Chimeric Antigen Receptor (CAR) T Cells Per kg"},{"description":"Participants who have not had an allogeneic hematopoietic stem cell transplant. 3.0x10\\^6 Chimeric Antigen Receptor (CAR) T cells per kg of recipient bodyweight\n\n3.0x10\\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) infuse on day 0 and Cyclophosphamide: This chemotherapy dose was changed part-way through the protocol, thus 4 participants received 500 mg/m\\^2 and 3 participants received 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg/m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3.","id":"FG003","title":"Dose Escalation Cohort 1 Dose Level 3 - 3.0x10^6 Chimeric Antigen Receptor (CAR) T Cells Per kg"},{"description":"Participants who have not had an allogeneic hematopoietic stem cell transplant. 9.0x10\\^6 Chimeric Antigen Receptor (CAR) T cells per kg of recipient bodyweight\n\n9.0 x10\\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) infuse on day 0 and Cyclophosphamide: 500 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg/m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3","id":"FG004","title":"Dose Escalation Cohort 1 Dose Level 4 - 9.0x10^6 Chimeric Antigen Receptor (CAR) T Cells Per kg"},{"description":"18x10\\^6 Chimeric Antigen Receptor (CAR) T cells per kg of recipient bodyweight with a maximum dose of 216x10\\^7 CAR T cells.\n\nNo participants were enrolled on dose level 5.","id":"FG005","title":"Dose Escalation Cohort 1 Dose Level 5 - 18x10^6 Chimeric Antigen Receptor (CAR) T Cells Per kg"},{"description":"Participants who have had an Human Leukocyte Antigen (HLA)-matched sibling or an 8/8-HLA-matched unrelated donor transplant.\n\n1.0x10\\^6 Chimeric Antigen Receptor (CAR) T cells per kg of recipient bodyweight\n\n1.0 x10\\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) infuse on day 0 and Cyclophosphamide: 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg/m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3","id":"FG006","title":"Dose Escalation Cohort 2 Dose Level 1 - 1.0x10^6 Chimeric Antigen Receptor (CAR) T Cells Per kg"},{"description":"Participants who have had an Human Leukocyte Antigen (HLA)-matched sibling or an 8/8 HLA-matched unrelated donor transplant.\n\n3.0x10\\^6 Chimeric Antigen Receptor (CAR) T cells per kg of recipient bodyweight\n\n3.0x10\\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) infuse on day 0 and Cyclophosphamide: 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg/m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3","id":"FG007","title":"Dose Escalation Cohort 2 Dose Level 2 - 3.0x10^6 Chimeric Antigen Receptor (CAR) T Cells Per kg"},{"description":"Participants in this group were enrolled but not treated.","id":"FG008","title":"Cohort 1 No Level Assigned - Enrolled But Not Treated"},{"description":"Participants in this group were enrolled but not treated.","id":"FG009","title":"Cohort 2 No Level Assigned - Enrolled But Not Treated"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"}],"type":"Did not receive treatment."},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"Enrolled and removed from study with no treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"}],"type":"Chemotherapy was started and not finished & no Chimeric Antigen Receptor T-cells were administered."}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"comment":"One participant was enrolled and removed from study with no treatment and was later re-enrolled and treated.","groupId":"FG002","numSubjects":"4"},{"comment":"One participant was enrolled and removed from study with no treatment and was later re-enrolled and treated.","groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}